miRNA panel from HER2+ and CD24+ plasma extracellular vesicle subpopulations as biomarkers of early-stage breast cancer
HER2+ and CD24+ EV subpopulations contain complementary biomarkers suitable for validation in larger studies that can accurately detect early-stage breast cancer among women with BI-RADS category 4 breast lesions.
Authors
- Susan P. Weinstein (ORCID: https://orcid.org/0000-0001-6159-1500)
- Michael D. Feldman (ORCID: https://orcid.org/0000-0002-9476-927X)
- Griffin B. Spychalski (ORCID: https://orcid.org/0000-0002-7210-6416)
- Kate Rollert French (ORCID: https://orcid.org/0000-0002-3721-8025)
- Andrew A. Lin (ORCID: https://orcid.org/0000-0001-7400-2285)
- Miriyam Ghali (ORCID: https://orcid.org/0000-0003-3876-4738)
- Sheau‐Fang Yang (ORCID: https://orcid.org/0000-0002-1773-3716)
- Erica L. Carpenter (ORCID: https://orcid.org/0000-0002-0735-3605)
- Stephanie S. Yee (ORCID: https://orcid.org/0000-0002-3469-9775)
- David Issadore (ORCID: https://orcid.org/0000-0002-5461-8653)
- Emily F. Conant (ORCID: https://orcid.org/0000-0001-9331-644X)
- Anupma Nayak (ORCID: https://orcid.org/0000-0002-7445-1897)
- Kyle Tien
- J. Fernando del Rosario (ORCID: https://orcid.org/0000-0002-5826-8013)
- Melinda Yin
- Hanfei Shen (ORCID: https://orcid.org/0009-0009-1428-6584)
Institutions
- University of Pennsylvania (US)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1186/s13058-025-02029-2
- Citations
- 7
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 5.64
Funders
- University of Pennsylvania
- National Institutes of Health
- Penn Center for Precision Medicine, University of Pennsylvania
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases